The Dorothy Schachne Partners In Progress Award presented to

Accepting the award on behalf of ASCO

Dr. Clifford Hudis, Chief Executive Officer, ASCO; Executive Vice Chair, Conquer Cancer, the ASCO Foundation

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice-Chair of its Conquer Cancer Foundation. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s more than 50,000 members in more than 170 countries.

The Dorothy Schachne Corporate Achievement Award presented to

Accepting on behalf of Petauri

Dan Renick for Petuari, Chief Executive Officer

A well-known executive in the life sciences industry, Dan Renick has more than 28 years of healthcare experience. He provides visionary leadership to life sciences innovators with highly effective, strategic, and pragmatic solutions to commercialization challenges. As CEO of Petauri, he is applying this experience in partnership with clients to ensure that scientific breakthroughs reach patients with unmet medical needs through Petauri's data-driven, digital-forward expert solutions.

Prior to forming Petauri in partnership with Oak Hill Capital Partners, Dan was a founding executive and President of Precision Value & Health following their acquisition of Hobart Group Holdings in 2013. Under Dan’s leadership, Precision Value & Health experienced outsized organic growth, completed numerous strategic acquisitions, and received multiple industry awards and accolades.

At Humana, Inc., Dan served as Director of Corporate Pharmacy Management. In this role, he was responsible for pharmacy programs and trade relations, including oversight of contracting with pharmaceutical companies and pharmacy provider organizations. Dan also held the position of National Director of Pharmacy Networks, partnering with pharmacy channel stakeholders to improve access and quality in a cost-efficient manner. Earlier in his career, Dan was a Corporate Account Executive at Merck, working with large employers, business coalitions, and benefits consultants to facilitate rational, evidence-based healthcare decisions.

Dan has consistently been recognized as an industry leader, including: Top 10 Innovation Catalyst by Medical Marketing and Media (MM&M); PM360 ELITE Transformational Leader award winner, which recognizes 100 of the most influential people in the healthcare industry; strategic industry leader recognition by American Healthcare Leader; and featured by Pharmaceutical Commerce, among others.

Dan received a pharmacy degree from the University of Kentucky and a BS in chemistry and biology from Western Kentucky University.

Accepting on behalf of Bluprint Oncology

Lisa Hefner, President, Bluprint Oncology

Lisa is a 25-year oncology and hematology education and marketing expert. Her commitment to the oncology community, specifically the patients who are living with cancer and the desire to create a different type of communications agency are her biggest motivators.

Having broad experience in oncology and hematology, both on the manufacturer and agency side, Lisa understands the challenges of healthcare teams who make treatment -decisions for their patients and is dedicated to finding thoughtful solutions for Life Science partners to educate those treatment teams and their patients.

With the satisfaction of these stakeholders in mind, and with a targeted, evolved way of thinking, Lisa knew that to keep up with the innovations and complexities of oncology and hematology, a new approach and lens needed to be explored.

In 2016, she partnered to create Brightly Network LLC, consisting of medical communications agencies, BluPrint Oncology, and Verascity Science, establishing a space where clients are confidently supported, patients and HCPs are integral to the conversation, and employees can grow and thrive. Her paradigm-shifting strategies and solutions have quickly led BluPrint Oncology and Verascity Science to become thriving businesses supporting diverse life science clients.

Lisa’s partnerships in advocacy have brought patients and caregivers front and center to provide their voice to the conversations about healthcare. And her relationships with thought leaders in oncology and hematology have ensured BluPrint and Verascity are always on top of trends in treatment and care.

At 9 years old, companies focus on being brave, bold, curious, and adaptable. This is exemplified by the dozens of life science partners trusting her with their brands and changing how agencies build the best teams. Lisa is the person who brings everyone together, the critical catalyst to affecting positive change.

Lisa is the person who brings everyone together, the critical catalyst to affecting positive change. She is changing how agencies build the best teams, how agencies support clients with seats at the table when planning a strategy. That change moves us forward in improving healthcare and lives. Her passion makes a difference for patients living with cancer.

She and her entrepreneur husband, Joe Masiello, are raising two boys while living in NYC